

DRUG QUANTITY MANAGEMENT POLICY – PER RX

- POLICY:** Nonsteroidal Anti-Inflammatory Drug – Tivorbex Drug Quantity Management Policy – Per Rx
- Tivorbex® (indomethacin capsules – Basiem, generic)

REVIEW DATE: 06/08/2022

OVERVIEW

Tivorbex, a nonsteroidal anti-inflammatory drug (NSAID), indicated for treatment of mild to moderate acute pain in adults.¹

Dosing

For treatment of mild to moderate acute pain, the recommended dose of Tivorbex is 20 mg three times daily or 40 mg two or three times daily.¹ Tivorbex should be used at the lowest effective dosage for the shortest duration consistent with the patient’s individual treatment goals. Different strengths and formulations of oral indomethacin are not interchangeable.

Availability

Tivorbex is available as 20 mg capsules in bottles containing 30 capsules each.¹ A branded generic to Tivorbex is also available.

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Tivorbex (branded generic). If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Automation: None.

Drug Quantity Limits

Product	Strength	Maximum Quantity per Rx
Tivorbex® (indomethacin capsules, branded generic)	20 mg capsules	90 capsules

CRITERIA

1. If the patient requires a dose of 40 mg twice daily, approve 120 capsules per dispensing.
2. If the patient requires a dose of 40 mg three times daily, approve 180 capsules per dispensing.

REFERENCES

1. Tivorbex® capsules [prescribing information]. Madisonville, LA: Basiem; April 2021.

06/08/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.